Release details

2016-02-03 10:00 CET
  • Print
  • Share Share

Nicox to present at the 18th Annual BIO CEO & Investor Conference

Nicox to present at the 18th Annual BIO CEO & Investor Conference


February 3, 2016

Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 10:00 a.m. Eastern Time. The conference is being held at The Waldorf Astoria hotel in New York City.

A live webcast of the BIO CEO & Investor Conference presentation can be accessed on the company's website ( in "News & Media > Presentations & webcasts". A replay of the webcast will be archived on Nicox's website for 90 days following the date of the presentation.


About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight.

Nicox's advanced pipeline features latanoprostene bunod for the lowering of intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, and for which a New Drug Application (NDA) was submitted to the FDA by the Company's licensee Valeant. The Company's pipeline also features AC-170, a pre-NDA candidate for the treatment of ocular itching associated with allergic conjunctivitis, as well as two pre-MAA candidates in Europe: AzaSite® for bacterial conjunctivitis and BromSite(TM) for pain and inflammation after cataract surgery. Beyond these late-stage candidates, Nicox is developing a pipeline of next generation ophthalmology-focused candidates which utilize its proprietary nitric oxide (NO)-donating research platform. The Group has operations in Europe and the United States.

Nicox is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its commercial products or pipeline, please visit


Analyst coverage

Bryan, Garnier & Co       Hugo Solvet                    Paris, France
Invest Securities             Martial Descoutures       Paris, France
Gilbert Dupont                Damien Choplain           Paris, France

Upcoming 2016  events

Financial and business conferences
Feb. 8-9                           BIO CEO & Investor  Conference       New York, US
April 12-13                       Needham Healthcare Conference      New York, US  
May 17                             SFAF Bio Day                                       Paris, France
June 6-9                          BIO 2016                                                San Francisco, US

Nicox                              Gavin Spencer | Executive Vice President Corporate Development
                                        Caroline Courme | Communication Manager
                                        Tel +33 (0)4 97 24 53 00 |    

Media Relations           

United Kingdom               Jonathan Birt
                                        Tel +44 7860 361 746 |

France                            NewCap | Nicolas Merigeau
                                        Tel +33 (0)1 44 71 94 98 |   

United States                  Argot Partners | Eliza Schleifstein
                                        Tel +1 (917) 763-8106 |

Investor Relations       

Europe                            NewCap | Julien Perez | Valentine Brouchot
                                        Tel +33 (0)1 44 71 94 94 |

United States                  Argot Partners | Melissa Forst
                                        Tel +1 (212) 600-1902 |

This press release contains certain forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the 'Document de référence, rapport financier annuel et rapport de gestion 2014' filed with the French Autorité des Marchés Financiers (AMF) on April 10, 2015, which is available on Nicox's website (

Nicox S.A. Drakkar 2 | Bât D | 2405 route des Dolines | CS 10313 | Sophia Antipolis | 06560 Valbonne | France T: +33 (0)4 97 24 53 00   |   F: +33 (0)4 97 24 53 99